DNA makes RNA, RNA makes protein, protein makes phenotype—was the guiding framework for understanding inheritance and disease ...

Class Precision Medical AI Platform with Vanderbilt University Medical Center SEOUL, South Korea, July 10, 2025 ...

BACKGROUND: Direct reprogramming of fibroblasts to cardiomyocytes is a potentially curative strategy for ischemic heart ...

The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673)- -Independent Data Safety Monitoring Boar ...

In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673)- ...

LG AI Research on Wednesday unveiled its next-generation artificial intelligence model, Exaone Path 2.0, which can diagnose ...

After years of development, the company says it’s now gearing up for human clinical trials of cancer drugs, treatments ...

RNA is emerging as a valuable target for the development of novel therapeutic agents. The rational design of RNA-targeting small molecules, however, has been hampered by the relative lack of methods ...

In this interview, Professor James J. Collins, founder of the field of Synthetic Biology, discusses his journey to founding ...

If a gene is evolutionarily conserved, that shows it must be doing something important. Otherwise, nature would let it go.

Advancements in manufacturing technologies is a key driver driving nucleic acid therapeutics CDMO market revenue growth.